SMS Pharmaceuticals Limited (SMSPHARMA.NS)
INR 217.06
(1.89%)
INR 217.06
(1.89%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.34 Billion INR | 212.15% |
| 2022 | 272.64 Million INR | -66.82% |
| 2021 | 821.76 Million INR | -16.88% |
| 2020 | 988.63 Million INR | 70.43% |
| 2019 | 580.09 Million INR | -18.15% |
| 2018 | 708.73 Million INR | -3.54% |
| 2017 | 734.75 Million INR | -6.39% |
| 2016 | 784.87 Million INR | 10.04% |
| 2015 | 713.29 Million INR | 3.23% |
| 2014 | 690.94 Million INR | 55.92% |
| 2013 | 443.12 Million INR | 211.85% |
| 2012 | -396.18 Million INR | -257.49% |
| 2011 | 251.55 Million INR | -29.11% |
| 2010 | 354.84 Million INR | 47.58% |
| 2009 | 240.44 Million INR | -12.85% |
| 2008 | 275.89 Million INR | -39.76% |
| 2007 | 457.97 Million INR | 5.1% |
| 2006 | 435.74 Million INR | 94.1% |
| 2005 | 224.5 Million INR | 20.47% |
| 2004 | 186.35 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 251.29 Million INR | -2.22% |
| 2023 Q3 | 224.79 Million INR | 8.43% |
| 2023 FY | 851.03 Million INR | 212.15% |
| 2023 Q1 | 190.05 Million INR | 18.2% |
| 2023 Q2 | 207.31 Million INR | 9.08% |
| 2023 Q4 | 257.01 Million INR | 14.33% |
| 2022 Q1 | -87.43 Million INR | 28.21% |
| 2022 Q3 | 126.04 Million INR | 107.21% |
| 2022 Q4 | 160.78 Million INR | 27.57% |
| 2022 Q2 | 60.82 Million INR | 169.57% |
| 2022 FY | 272.64 Million INR | -66.82% |
| 2021 FY | 821.76 Million INR | -16.88% |
| 2021 Q2 | 387.05 Million INR | 6.21% |
| 2021 Q1 | 364.43 Million INR | 2.41% |
| 2021 Q3 | 189.49 Million INR | -51.04% |
| 2021 Q4 | -121.79 Million INR | -164.27% |
| 2020 Q1 | 159.48 Million INR | 86.06% |
| 2020 Q2 | 180.58 Million INR | 13.23% |
| 2020 FY | 988.63 Million INR | 70.43% |
| 2020 Q4 | 355.87 Million INR | 23.42% |
| 2020 Q3 | 288.35 Million INR | 59.68% |
| 2019 Q4 | 85.71 Million INR | -41.44% |
| 2019 Q1 | 181.03 Million INR | 70.06% |
| 2019 Q2 | 168.33 Million INR | -7.02% |
| 2019 Q3 | 146.36 Million INR | -13.05% |
| 2019 FY | 580.09 Million INR | -18.15% |
| 2018 FY | 708.73 Million INR | -3.54% |
| 2018 Q3 | 207.67 Million INR | 1.27% |
| 2018 Q2 | 205.08 Million INR | 8.21% |
| 2018 Q1 | 189.52 Million INR | 0.0% |
| 2018 Q4 | 106.45 Million INR | -48.74% |
| 2017 FY | 734.75 Million INR | -6.39% |
| 2016 Q2 | 228.01 Million INR | 25.25% |
| 2016 Q1 | 182.04 Million INR | 1.62% |
| 2016 FY | 784.87 Million INR | 10.04% |
| 2015 Q2 | 180.06 Million INR | 31.66% |
| 2015 Q3 | 217.32 Million INR | 20.69% |
| 2015 Q4 | 179.13 Million INR | -17.57% |
| 2015 FY | 713.29 Million INR | 3.23% |
| 2015 Q1 | 136.76 Million INR | 9.25% |
| 2014 Q1 | 142.04 Million INR | -16.77% |
| 2014 FY | 690.94 Million INR | 55.92% |
| 2014 Q4 | 125.18 Million INR | -58.47% |
| 2014 Q3 | 301.46 Million INR | 146.6% |
| 2014 Q2 | 122.24 Million INR | -13.94% |
| 2013 Q3 | 174.72 Million INR | 82.0% |
| 2013 Q4 | 170.65 Million INR | -2.33% |
| 2013 FY | 443.12 Million INR | 211.85% |
| 2013 Q2 | 96 Million INR | 5443.07% |
| 2013 Q1 | 1.73 Million INR | 100.82% |
| 2012 FY | -396.18 Million INR | -257.49% |
| 2012 Q2 | -107.92 Million INR | -466.1% |
| 2012 Q1 | 29.47 Million INR | -34.5% |
| 2012 Q3 | -100.48 Million INR | 6.89% |
| 2012 Q4 | -210.14 Million INR | -109.14% |
| 2011 FY | 251.55 Million INR | -29.11% |
| 2011 Q4 | 45 Million INR | -37.21% |
| 2011 Q3 | 71.67 Million INR | 0.0% |
| 2010 FY | 354.84 Million INR | 47.58% |
| 2009 FY | 240.44 Million INR | -12.85% |
| 2008 FY | 275.89 Million INR | -39.76% |
| 2007 FY | 457.97 Million INR | 5.1% |
| 2006 FY | 435.74 Million INR | 94.1% |
| 2005 FY | 224.5 Million INR | 20.47% |
| 2004 FY | 186.35 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott India Limited | 13.79 Billion INR | 90.285% |
| Cipla Limited | 105.7 Billion INR | 98.732% |
| Gland Pharma Limited | 16.45 Billion INR | 91.854% |
| GlaxoSmithKline Pharmaceuticals Limited | 13.6 Billion INR | 90.147% |
| Kopran Limited | 675.44 Million INR | -98.409% |
| Marksans Pharma Limited | 7.79 Billion INR | 82.8% |
| NGL Fine-Chem Limited | 416.27 Million INR | -221.941% |
| Pfizer Limited | 9.61 Billion INR | 86.057% |
| Sanofi India Limited | 12.19 Billion INR | 89.009% |
| TTK Healthcare Limited | 249.89 Million INR | -436.294% |